Search for Clinical Trial Results

Sponsored By

Inflammatory Myofibroblastic Tumor - 7 Studies Found

Status Study
No longer available Study Name: Treatment With Crizotinib Single Patient Expanded Access IND 134375
Condition: Inflammatory Myofibroblastic Tumour
Date: 2017-03-14
Interventions: Drug: Crizotinib
Enrolling by invitation Study Name: Low-dose Protocol for Computed Tomography-guided Lung Biopsy
Condition:
  • Lung Cancer, Adenocarcinoma
  • Lung Inflammatory Pseudotumor

    • Date: 2016-11-17
    Interventions:
    • Radiation: Low-dose protocol computed tomography

Enrolling by invitation Study Name: A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
Condition:
  • Advanced Malignancies
  • Carcinoma, Non-Small-Cell Lung
  • Anapl
    Date: 2011-09-30
    Interventions: Drug: AP26113 30 mg tablet(s) taken orally and increasing in increments until the maximum tolerated dose
Recruiting Study Name: Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)
Condition: Anaplastic Lymphoma Kinase (ALK)
Date: 2012-11-30
Interventions: Drug: LDK378 LDK378 is a capsule taken by mouth, contents can be mixed with food for pediatric patients
Recruiting Study Name: CREATE: Cross-tumoral Phase 2 With Crizotinib
Condition:
  • Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma
  • Locally Advanced and/or Me
    Date: 2012-01-24
    Interventions: Drug: Crizotinib (PF-02341066) For patients of 15yo and older, Capsules of 200 and 250 mg Daily dose of
Recruiting Study Name: Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
Condition:
  • Adult Fibrosarcoma
  • Alveolar Soft Part Sarcoma
  • Angiomatoid
    Date: 2014-07-01
    Interventions:
    • Drug: Doxorubicin Hydrochloride

Recruiting Study Name: Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer
Condition:
  • Advanced Solid Tumors
  • Non-small Cell Lung Cancer

Date: 2012-06-15
Interventions: Drug: X-396 (ensartinib) Oral, ALK inhibitor